Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1789876 | 0.84 | RPS6KB1 (0.56) | RPS6KB1MAPTLMNATP53ALDH1A1 | |
| SCHEMBL1789872 | 0.84 | RPS6KB1 (0.56) | RPS6KB1MAPTLMNATP53ALDH1A1 | |
| SCHEMBL4934183 | 0.79 | RPS6KB1 (0.51) | RPS6KB1MAPTLMNATP53ALDH1A1 | |
| SCHEMBL4934175 | 0.79 | RPS6KB1 (0.51) | RPS6KB1MAPTLMNATP53ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4932731 | 0.79 | RPS6KB1 (0.51) | RPS6KB1MAPTLMNATP53SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4932722 | 0.79 | RPS6KB1 (0.51) | RPS6KB1MAPTLMNATP53SMN1; SMN2 | |
| SCHEMBL1793442 | 0.78 | RPS6KB1 (0.59) | RPS6KB1MAPTLMNATP53ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4930335 | 0.75 | RPS6KB1 (0.49) | RPS6KB1MAPTLMNATP53SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4930339 | 0.75 | RPS6KB1 (0.49) | RPS6KB1MAPTLMNATP53SMN1; SMN2 | |
| SCHEMBL1792919 | 0.75 | RPS6KB1 (0.59) | RPS6KB1MAPTLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | RPS6KB1 329/4885MAPT 4242/4885LMNA 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.